Forecasting The Future: 18 Analyst Projections For Biogen

Loading...
Loading...

During the last three months, 18 analysts shared their evaluations of Biogen BIIB, revealing diverse outlooks from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 6 8 4 0 0
Last 30D 1 0 0 0 0
1M Ago 0 1 0 0 0
2M Ago 5 7 3 0 0
3M Ago 0 0 1 0 0

Insights from analysts' 12-month price targets are revealed, presenting an average target of $302.44, a high estimate of $364.00, and a low estimate of $240.00. Experiencing a 5.59% decline, the current average is now lower than the previous average price target of $320.36.

Interpreting Analyst Ratings: A Closer Look

In examining recent analyst actions, we gain insights into how financial experts perceive Biogen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Robyn Karnauskas Truist Securities Maintains Buy $340.00 -
Brian Abrahams RBC Capital Maintains Outperform $364.00 -
Salim Syed Mizuho Lowers Buy $277.00 $355.00
Eric Schmidt Cantor Fitzgerald Maintains Overweight $311.00 -
Sumant Kulkarni Canaccord Genuity Lowers Buy $305.00 $310.00
Colin Bristow UBS Lowers Neutral $250.00 $276.00
Brian Skorney Baird Lowers Outperform $316.00 $333.00
Christopher Raymond Piper Sandler Lowers Overweight $325.00 $350.00
Evan Seigerman BMO Capital Lowers Outperform $285.00 $295.00
Jay Olson Oppenheimer Lowers Outperform $290.00 $295.00
Brian Abrahams RBC Capital Lowers Outperform $364.00 $379.00
Mohit Bansal Wells Fargo Lowers Equal-Weight $240.00 $315.00
Andrew Fein HC Wainwright & Co. Maintains Buy $325.00 -
Ami Fadia Needham Lowers Buy $300.00 $305.00
Ami Fadia Needham Maintains Buy $305.00 -
Jay Olson Oppenheimer Maintains Outperform $295.00 -
Colin Bristow UBS Lowers Neutral $276.00 $311.00
Colin Bristow UBS Announces Neutral $276.00 -

Key Insights:

Loading...
Loading...
  • Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Biogen compared to the broader market.
  • Price Targets: Delving into movements, analysts provide estimates for the future value of Biogen's stock. This analysis reveals shifts in analysts' expectations over time.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Biogen's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Biogen analyst ratings.

Get to Know Biogen Better

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

A Deep Dive into Biogen's Financials

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Challenges: Biogen's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -6.2%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Biogen's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 10.46%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): Biogen's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.71%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.91%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.5.

How Are Analyst Ratings Determined?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...